{"entity":{"id":"nct04465968","kind":"trial","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","aka":["DEEP_OCEAN"],"tldr":"A phase 3 trial of cisplatin and durvalumab in lung cancer, run by National Cancer Center Hospital East, not yet recruiting.","summary":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST is a phase 3, interventional study registered as NCT04465968 by National Cancer Center Hospital East, with a registry enrolment figure of 84 participants, started 2020-09-01 and due to reach its primary completion in 2027-08-31. Interventions recorded: Cisplatin; S1; concurrent radiotherapy; Durvalumab; Surgery; Durvalumab. Conditions listed: Superior Sulcus Tumor; Non-small Cell Lung Cancer Stage IIB; Non Small Cell Lung Cancer Stage III. Primary outcome: 3-year overall survival rate (3y-OS). Lung eligibility wording from the registry: \"A definite diagnosis of non-small cell lung cancer has been obtained by biopsy from the primary lesion\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04465968","url":"https://clinicaltrials.gov/study/NCT04465968"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["cisplatin","durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04465968","phase":"3","setting":"Efficacy and Safety of Durvalumab Before and After Operation or Durvalumab as Maintenance Therapy After Chemoradiotherapy Against Superior Sulcus Non-small Cell Lung Cancer","sponsor":"National Cancer Center Hospital East","enrolled":84,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04465968/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}